both comparisons). Prescribed medications were similar for both groups in regards to synthetic disease modifying antirheumatic drugs (DMARDs), biologics, and opioids, although those with PTSD were significantly more likely to receive NSAIDs (p = 0.03). Veterans with AS and comorbid PTSD were younger and had higher reported pain and disease activity scores compared to those without PTSD in this single site study. These findings underscore the importance of identifying PTSD in patients with AS.
Introduction
Posttraumatic stress disorder (PTSD) is diagnosed in individuals who were exposed to traumatic events and whose function is affected by intrusive re-experiencing of these events, as well as symptoms of avoidance and hyperarousal [1] . In a study of nearly 750 Veterans, PTSD was found to have an 11.5% prevalence in the Veterans Affairs (VA) outpatient setting [2] . PTSD is associated with significant comorbidities including an increased risk of incident rheumatoid arthritis (RA) in male Vietnam-era veterans, as well as female nurses in the civilian population [3] [4] [5] . Among Veterans with RA, PTSD was associated with higher reported pain scores [6] .
It is unknown whether PTSD is associated with an increased incidence of ankylosing spondylitis (AS) or whether it affects disease outcomes. Overall, individuals with AS have poorer function and quality of life than the general population, which translates to increased healthcare utilization and costs [7, 8] . The 2014 Treat to Target guidelines for spondyloarthritis (SpA) recommend recording Abstract The objective of this retrospective study was to evaluate the prevalence of comorbid Posttraumatic stress disorder (PTSD) and the association of PTSD with pain, disease activity, and medication use in ankylosing spondylitis (AS). Veterans with one or more visit to an outpatient rheumatology clinic at a single Veterans Affairs site during a 2-year study period were identified by ICD codes for AS and included if there was documentation of AS diagnosis by a rheumatologist. Data were collected on PTSD diagnosis, demographics, pain scores, disease activity by the Bath AS Disease Activity Index (BASDAI), and medication use. Characteristics were compared by PTSD status using t tests for continuous variables and Chi-square or Fischer's exact test for categorical variables. Of 113 Veterans with AS, 20 (18%) had a diagnosis of PTSD. Those with PTSD were significantly younger, 52 ± 17 years, as compared to those without PTSD, 59 ± 14 years (p = 0.04). BAS-DAI was recorded for 30% with a mean score of 4.3 ± 2.0. Those with PTSD had higher mean pain and BASDAI scores as compared to those without PTSD (p = 0.06 for disease activity via validated instruments such as the Bath AS Disease Activity Index (BASDAI), and monitoring for treatment response [9] . This is especially prudent as increased disease activity in AS has been associated with increased mortality [10] .
The objective of this retrospective study was to evaluate the prevalence of comorbid PTSD and the association of PTSD with pain levels, disease activity, and medication use in AS.
Materials and methods

Participants
Subjects were identified using VA's Corporate Data Warehouse, a collection of multiple relational databases containing comprehensive and aggregated VA patient electronic medical record data. Subjects were included in this study if they had one or more rheumatology clinic visits at a single VA medical center between 1 January 2014 and 31 December 2015, had an ICD-9 or ICD-10 code for AS (ICD-9 of 720.0 or ICD-10 of M45.0 with related ICD-10 codes M45.1, M45.2, M45.3, M45.4, M45.5, M45.6, M45.7, M45.8), had at least one documented pain intensity score during the 2-year period and whose AS diagnosis was also confirmed by a rheumatologist. Pain was measured by the single-item 11-point Numeric Rating Scale during clinic visits. Subjects with diagnoses other than AS confirmed during chart review were excluded. Approval for this study was granted by the institutional review board of the Veterans Affairs Portland Health Care System.
Data collection
Review of VA electronic medical record was conducted to collect information on age, gender, race, PTSD status, pain intensity score, medication use, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and disease activity as measured using the BASDAI when documented by the primary rheumatologist. The BASDAI is a patient-reported outcome measure which consists of six items assessing fatigue, axial joint pain, peripheral joint pain, soft tissue tenderness to touch, and severity and duration of morning stiffness [11] . Medication use, by class, was determined by current prescription list in the clinic note of the most recently documented BASDAI score.
Statistical analysis
Descriptive statistics were used to characterize differences in patient demographics, pain intensity scores, BASDAI score and medication use between subjects with PTSD and those without. Specifically, bivariable relationships between PTSD and no PTSD groups and age (continuous), gender, white versus non-white race/ethnicity, pain (continuous, 0-10), and BASDAI score (continuous) were assessed. ESR and CRP were not included in the final analysis due to insufficient number of data points. Bivariable relationships between PTSD status and medication use (NSAID, synthetic disease modifying anti-rheumatic drugs or DMARDs and biologics) were also assessed. Chi-square or Fischer's exact test were used for categorical variables and student's t tests for continuous variables. All analyses were performed using Stata/SE, version 13.1 (StataCorp LP, College Station, TX).
Results
Of 136 veterans with ICD-9 or ICD-10 codes for AS identified during the study period, 113 had a rheumatologist diagnosis for AS and were included in the study. Of the 23 excluded, two individuals did not have rheumatology clinic visits during the study period, and 21 did not have a rheumatologist-confirmed diagnosis for AS.
Of the 113 veterans with confirmed AS, 20 (18%) had a diagnosis of PTSD. Both populations were mostly male (95% for both those with and without PTSD) and white (90% overall; 100% for those with PTSD, 88% for those without PTSD). Veterans with PTSD were significantly younger, with a mean age of 52 ± 17 years as compared to those without PTSD, who had a mean age of 59 ± 14 years (p = 0.04).
Mean pain intensity scores were higher for those with PTSD versus those without (4.9 ± 2.4 vs. 3.6 ± 2.8, p = 0.06). The BASDAI was recorded for 35 patients (30%), 6 of whom had PTSD, with a mean score of 4.3 ± 2.0. Those with PTSD had higher mean BASDAI scores as compared to those without PTSD (5.7 ± 2.7 vs. 4.0 ± 1.8, p = 0.06), in a trend towards significance (Table 1) .
Prescribed medications (Fig. 1) were similar for both groups in regards to synthetic DMARDs (10% vs. 15%), biologics (60% vs. 52%), and opioids (15% vs. 24%). Those with PTSD were significantly more likely to receive NSAIDs (70% vs. 42%, p = 0.03).
Discussion
To our knowledge, this retrospective single-center study is the first to examine the association between comorbid PTSD and disease activity in AS. This study demonstrates that Veterans with AS and concomitant PTSD have higher reported pain and disease activity scores compared to those without PTSD, differences which approach statistical significance. Increased disease activity is a significant predictor of healthrelated quality of life in Veterans with SpA [7] , and has been found to be associated with increased radiographic progression as well as increased mortality in AS [10, 12, 13] . The identification of PTSD as a specific factor associated with poorer outcomes in AS has not been previously shown.
The co-occurrence of PTSD with chronic pain is common [14, 15] . Concurrent PTSD may also lead to overestimation of disease activity in individuals with AS, which may then lead to the escalation of DMARD and biologic therapies for pain and fatigue that are not associated with underlying inflammation. As a study by Wach et al. has shown, the BASDAI overestimates disease activity if there is concurrent fibromyalgia [16] . Similarly, in a study by Mikuls et al. on the relationship between PTSD and disease activity in US Veterans with RA, concomitant PTSD was associated with a significant increase in patient-reported outcomes such as pain and physical impairment, but not objective measures such as swollen joint count or inflammatory markers [6] . The same phenomenon may exist for PTSD and AS.
The current study did not show significant differences in medications prescribed for AS, apart from NSAIDs, which were more frequently prescribed to those with PTSD and AS. Notably, patients with AS and PTSD did not have a higher incidence of prescribed opioids compared to those without PTSD. This finding contrasts with studies which show that Veterans with PTSD and pain conditions are more likely to be prescribed opioids and at higher doses [17] , and have been reported to have higher healthcare utilization than those with either PTSD or pain alone [18] . Veterans or patients with concomitant AS and PTSD need to be better identified in the outpatient rheumatology population, as optimal treatment involves a multidisciplinary approach involving behavioral or mental health, particularly if there is concurrent chronic pain [19] .
Subjects in this study overall had an average BASDAI of 4.3, which indicates active disease. There may be factors other than PTSD which account for this higher disease (15) 2 (10) 15 ( activity, such as smoking status, socioeconomic status, work disability, and other mental health conditions. Provider adherence to documentation of BASDAI was low in this study (30%), despite recent treat to target guidelines for AS which recommend regular documentation of disease activity to assist in monitoring treatment response. Possible barriers to documentation of disease activity include limited time during office visits, technological difficulties accessing the BASDAI, and issues with embedding it in the electronic medical record. Veterans with AS and PTSD this study were also significantly younger than those without PTSD. It is possible that younger Veterans are more likely to be diagnosed with PTSD than older Veterans, although recent studies cite the prevalence of PTSD in returning Veterans from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) to be 15-17%, whereas the prevalence of PTSD in Vietnam veterans is up to 30% [2, 20] . We also found a relatively high prevalence of PTSD in our outpatient rheumatology clinic: 18% as compared to 11.5% in Magruder's 2005 study [2] . This may have been due to chance variation or regional variation. PTSD could possibly lead to an increased risk of incident AS as has been identified in RA [4, 5] .
Despite the strengths and unique findings of this study, there are several limitations. This is a retrospective, observational study conducted through chart review, which limits the ability to infer causality among associations. It was performed at a single VA center, which limits its generalizability to other non-VA populations. Notably, the VA population is mainly male and Caucasian, so these findings may not apply to female or minority populations. The study was small, which limited our ability to adjust for potential confounders, and may be underpowered to show differences that may exist in a larger population. Individuals were initially identified for inclusion by ICD-9 or 10 code. Although a study showed that ICD-9 codes are accurate for the diagnosis of SpA in the VA database, with a sensitivity of 98-100% and specificity of 91% [21] , cases may have been missed, and individuals who did not truly have AS may have been misclassified. Similarly, the diagnosis of PTSD was determined by either an ICD-9 or 10 code for this condition, as well as by documentation in the chart. The ICD-9 code for PTSD has been shown to be valid in the VA database in one study [22] , but may also misclassify some individuals. Patient-reported pain intensity scores may be confounded by the variable way in which individuals experience and report their pain as well as variation in administration of the NRS [23] . Similarly, disease activity as documented by the BASDAI is also subjective and may be confounded by chronic pain disorders. Objective markers of inflammation such as ESR and CRP were not included in the statistical analysis due to missing data. Other potential factors that may affect disease activity in AS, such as smoking status, socioeconomic status, work disability, presence of fibromyalgia, presence of other mental health conditions, or axial versus peripheral disease were not captured in this study.
This study highlights the future work that is yet to be done. The association of pain and PTSD on disease activity in AS is in need of further elucidation. In the same vein, more objective measures of disease activity than the BASDAI could be sought. The AS Disease Activity Score (ASDAS) which uses weighted variables as well as ESR or CRP, may provide a more objective measure [24, 25] . The effect of PTSD on correlates of disease activity could be further identified, including the interaction with other factors known to effect disease activity in AS. Finally, PTSDinformed treatment should be advocated in rheumatology, as it has been advocated in the primary care setting.
Conclusion
Veterans with AS and concomitant PTSD are younger and have higher reported pain and disease activity scores compared to those without PTSD in this single site study. This study underscores the importance of identifying PTSD in patients with AS who report higher pain and disease activity. Future research should include identifying and treating concomitant mental health disorders in Veterans with AS, as other studies have shown improvement in chronic pain with treatment of PTSD.
